The Marshall Protocol Study Site Home

Search
   
Members

Calendar

Help

Home
Search by username
   Not logged in - Login | Register 


FDA investigating the safety of Benicar
 Moderated by: Prof Trevor Marshall Page:  First Page Previous Page  ...  4  5  6  7  8  9  10  11  12  13  14  Next Page Last Page  
 

New Topic

Reply

Print
AuthorPost
Prof Trevor Marshall
Foundation Staff


Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 15717
Status:  Offline
 Posted: Fri Mar 18th, 2011 00:15

Quote

Reply
An average 40mg every 4-6 hours is our current guidance. It is better to take 40mg than 20mg, as the higher peak concentration has a greater effect on the nuclear receptors. But by juggling the dose, and interval, one has some minimal control over the balance between IP and immunostimulation.

tammy1000
inactive member
 

Joined: Wed Apr 7th, 2010
Location: USA
Posts: 68
Status:  Offline
 Posted: Fri Mar 18th, 2011 05:58

Quote

Reply
Thank you, Dr. Marshall. We appreciate your guidance. ;)



____________________
VitD restr. Dec'08, Problems w/Olm '09-'10, Presently: 40mg Olm @6hrs; 88' Severe MCS/allergies, asthma, cognitive, arthritis, bone loss, periodontal
eClaire
member


Joined: Sun Sep 24th, 2006
Location: Newtownards, N. Ireland, United Kingdom
Posts: 1658
Status:  Offline
 Posted: Thu Mar 24th, 2011 02:33

Quote

Reply
Although some people report relief by taking olmesartan 20mg q2h, I discovered that, for me, while it got rid of the peak unpleasant response (brought on by the waning of the drug), I felt consistently uncomfortable to a greater degree taking 20mg q2h. For me, it is worth the sudden "Oh it must be time for my next Benicar" than to miss the positives that come with a 40mg dose.

I understand that this is person specific, but I'm glad that my experience coincides with the recommended best practices.

Last edited on Thu Mar 24th, 2011 02:34 by eClaire



____________________
Dec 2006, Olmesartan break Feb - April 2007, ME/Fibro/PTSD/MCS/Hypermobility (since childhood; disabled 2003); 25D summer 2012 <4 (meaning unable to detect)
Prof Trevor Marshall
Foundation Staff


Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 15717
Status:  Offline
 Posted: Thu Apr 14th, 2011 13:10

Quote

Reply
FDA has issued preliminary guidance:

http://www.fda.gov/Drugs/DrugSafety/ucm251268.htm

..Trevor..
 

Rico
Support Team
 

Joined: Tue May 30th, 2006
Location: Canada
Posts: 1339
Status:  Offline
 Posted: Thu Apr 14th, 2011 13:26

Quote

Reply
Relief that it isn't pulled off the shelves. Will Sankyo have any obligation to address the VDR agonist properties of Olmesartan in the "additional studies"?



____________________
No diagnosis/some symptoms (more than I knew); wife with Sarc on MP; Olm 40mg q4-6h | 25D=22 (May 2014) | 25D=27 (Nov 2014)
Prof Trevor Marshall
Foundation Staff


Joined: Fri Jul 9th, 2004
Location: Thousand Oaks, California USA
Posts: 15717
Status:  Offline
 Posted: Thu Apr 14th, 2011 13:34

Quote

Reply
Nope. Not unless Sankyo tells them about it. But that would open up a can of worms - Imagine the FDA suddenly having to recognize that all drugs hit multiple targets. Wow - in a short while there would be very few drugs left on the market, I reckon...

..Trevor..

Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Thu Apr 21st, 2011 02:20

Quote

Reply
No cancer risk elevation from ARBs: Two new analyses

http://www.theheart.org/article/1211465.do

"His group's findings, published online April 11, 2011 in Circulation, were based on the public-health records of >300 000 people in Denmark. They showed no significant rise in risk of incident cancer and even suggested reduced overall cancer mortality among those taking ARBs compared with others taking ACE inhibitors—independent of sex, type of ARB, and duration of ARB exposure"

Joyful
Foundation Staff


Joined: Fri Jun 8th, 2007
Location: USA
Posts: 14161
Status:  Offline
 Posted: Fri Apr 22nd, 2011 11:30

Quote

Reply
Thanks for that citation Bane. Good to have additional reassurance for those who worry. :)



____________________
Video • Be Kind, We Are All Fragile • Forums
`•.¸♥¸.•´`•.¸♥¸.•´`•.¸♥¸.•´`•.¸♥¸.•´`•.¸♥¸.•´
Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Sun Jun 5th, 2011 00:48

Quote

Reply
FDA Drug Safety Communication: No increase in risk of cancer with certain blood pressure drugs--Angiotensin Receptor Blockers (ARBs)

http://www.fda.gov/Drugs/DrugSafety/ucm257516.htm

The U.S. Food and Drug Administration (FDA) has completed a review of the potential risk of cancer associated with the class of medications known as angiotensin receptor blockers (ARBs). FDA has concluded that treatment with an ARB medication does not increase a patient’s risk of developing cancer.

Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Fri Jul 1st, 2011 03:47

Quote

Reply
Angiotensin Receptor Blockade and Risk of Cancer in Type 2 Diabetes Mellitus: A Nationwide Case-Control Study.

http://www.ncbi.nlm.nih.gov/pubmed/21690476

PURPOSE The objective of this case-control study was to evaluate the risk of malignancy in diabetic patients who received angiotensin receptor blockers (ARBs). PATIENTS AND METHODS A total of 21,750 new diabetic patients who started antihypertensive treatment were identified from the Taiwan National Health Insurance claims database during the period from July 1, 2000, to December 31, 2000. As of December 31, 2007, patients with incident cancer were included as cases and up to four age- and sex-matched controls were selected by risk-set sampling. Logistic regression models were applied to estimate the odds ratios (ORs) and 95% CIs between ARB use and cancer incidence, adjusted for other types of antihypertensive drugs, insulin, oral hypoglycemic agents, statins, and underlying diseases. Results Among the 1,281 patients with incident cancer and 5,104 controls, 333 (26.0%) and 1,341 (26.3%), respectively, received ARBs (OR, 0.98; 95% CI, 0.85 to 1.14). There was no statistically significant association between the effect of ARBs as a class and cancer incidence after adjustment for covariates (OR, 0.94; 95% CI, 0.80 to 1.10). Among the individual ARBs, losartan decreased the risk (OR, 0.78; 95% CI, 0.63 to 0.97) and candesartan (OR, 1.79; 95% CI, 1.05 to 3.06) and telmisartan (OR, 1.54; 95% CI, 0.97 to 2.43) possibly increased the risk of occurrence of malignancy. CONCLUSION The results did not show an effect of ARBs as a class on increasing cancer incidence in patients with diabetes. However, there was a negative association of losartan but a positive one of candesartan and telmisartan with the overall occurrence of cancer. The underlying mechanism certainly requires further investigation.

Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Fri Jul 1st, 2011 09:28

Quote

Reply
continuation

Study rekindles cancer-ARB question, this time in diabetics

http://www.theheart.org/article/1243675.do

"One explanation for this finding of null association is that cancer risk associated with ARBs might not be a class effect, and examining different ARBs as a group will dilute the risk estimates for individual drugs,"

"This new epidemiologic study not only shows an increased risk of cancer with candesartan, it also shows a very strong statistical trend toward increased risk with telmisartan," said Sipahi. "Now we have additional epidemiologic studies showing an increased risk of cancer with two different ARBs."

Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Mon Oct 3rd, 2011 05:07

Quote

Reply
More data reignite debate on ARB-lung cancer risk

http://www.theheart.org/article/1286017.do

"This is a nonrandomized observational study. I would think that smokers have higher risk of both cancer and severe cardiovascular disease. More severe CV disease [entails] more ACE inhibitors and ARBs; blaming these drugs would be like accusing the piano player of falsely singing. Confounded by indication cannot ever be corrected by multivariate adjustments in such a registry," says Kjeldsen.

 

Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins.

http://www.ncbi.nlm.nih.gov/pubmed/21936625

The use of ACE-inhibitors/ARBs, statins, and the combination of both were all associated with a reduced risk of breast cancer recurrence. This observation should prompt further exploration.

Last edited on Mon Oct 3rd, 2011 05:19 by Bane

Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Tue Oct 4th, 2011 03:04

Quote

Reply
Use of angiotensin-converting-enzyme inhibitors or angiotensin-receptor blockers and cancer risk: a meta-analysis of observational studies

http://www.cmaj.ca/content/183/14/E1073.full

Results: Of 3970 screened articles, 12 cohort studies and 16 case–control studies were selected for analysis. We found no significant association between the use of ACE inhibitors or angiotensin-receptor blockers and the overall risk of cancer (relative risk [RR] 0.96, 95% confidence interval [CI] 0.90–1.03). We found a decreased risk of cancer associated with use of either medication when we restricted the analyses to cohort and nested case–control studies (RR 0.90, 95% CI 0.83–0.97) or to studies with long-term follow-up of more than five years (RR 0.89, 95% CI 0.83–0.96). In the subgroup meta-analyses by cancer site, a decreased risk was identified for esophageal cancer, whereas an increased risk was found for melanoma and kidney cancer.

Interpretation: No significant association was found between the use of ACE inhibitors or angiotensin-receptor blockers and overall risk of cancer. A possible beneficial effect associated with use of either medication was suggested in sensitivity analyses, including those of studies with long-term follow-up. Large randomized controlled trials with long-term follow-up are needed to specifically test the effect of each of these medications on the risk of cancer.

Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Fri Oct 21st, 2011 00:56

Quote

Reply
EMA review concludes: No cancer risk with ARBs

http://www.theheart.org/article/1297005.do

"The CHMP reviewed all available data on the risk of cancer in patients taking ARBs, including the meta-analysis," the statement reads. "It found that the evidence from the meta-analysis was weak, noting several problems with the quality of the data, specifically that patients in the trials were not followed up for long enough to clearly establish a link between ARBs and cancer, information on the risk of cancer before start of treatment was lacking, and there was a possibility of publication bias, whereby studies that showed a link with cancer were more likely to have been included in the analysis."

As chronicled by heartwire over the past year, researchers have published a raft of studies and analyses either supporting or rejecting a link between ARBs and cancer, the most recent in the October 4, 2011 issue of CMAJ, by Dr Chan Yoon (Seoul National University of Medicine, South Korea) and colleagues, actually pointing to a beneficial effect of ARBs and ACE inhibitors on the risk of cancer. Another recent study, however, in diabetic patients treated with ARBs, suggested that candesartan (Atacand, AstraZeneca) was associated with a significant risk of cancer, while there was a trend toward an increased risk with telmisartan (Micardis, Boehringer Ingelheim).

Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Tue Jan 17th, 2012 01:10

Quote

Reply
Long-term use of drugs affecting the renin-angiotensin system and the risk of cancer. A population-based case-control study.
http://www.ncbi.nlm.nih.gov/pubmed/22243442

"No consistent dose-duration or dose-response association could be demonstrated for ARB or ACEI"

Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Wed Apr 25th, 2012 09:07

Quote

Reply
Angiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research Database

http://www.bmj.com/content/344/bmj.e2697

Results Follow-up ended a median of 4.6 years after the start of treatment; 20 203 cancers were observed. There was no evidence of any increase in overall risk of cancer among those ever exposed to angiotensin receptor blockers (adjusted hazard ratio 1.03, 95% confidence interval 0.99 to 1.06, P=0.10). For specific cancers, there was some evidence of an increased risk of breast and prostate cancer (1.11, 1.01 to 1.21, P=0.02; and 1.10, 1.00 to 1.20, P=0.04; respectively), which in absolute terms corresponded to an estimated 0.5 and 1.1 extra cases, respectively, per 1000 person years of follow-up among those with the highest baseline risk. Longer duration of treatment did not seem to be associated with higher risk (P>0.15 in each case). There was a decreased risk of lung cancer (0.84, 0.75 to 0.94), but no effect on colon cancer (1.02, 0.91 to 1.16).
Conclusions Use of angiotensin receptor blockers was not associated with an increased risk of cancer overall. Observed increased risks for breast and prostate cancer were small in absolute terms, and the lack of association with duration of treatment meant that non-causal explanations could not be excluded.


Bane
Research Team


Joined: Sat Jan 26th, 2008
Location: Norway
Posts: 974
Status:  Offline
 Posted: Sun May 27th, 2012 08:08

Quote

Reply
ACE inhibitors and angiotensin receptor blockers use and breast cancer outcomes in patients treated with neoadjuvant systemic chemotherapy.

http://abstract.asco.org/AbstView_114_96713.html

Conclusions: No differences in pCR and survival outcomes were seen between ACEI/ARB users and non-users among breast cancer patients receiving neoadjuvant chemotherapy. ARB use may be associated with improved relapse-free survival. Further research is needed to validate this finding.

HBOE
inactive member
 

Joined: Tue May 1st, 2012
Location: Dutte, Montana USA
Posts: 22
Status:  Offline
 Posted: Tue Jun 5th, 2012 14:28

Quote

Reply
This is my first posting on the official website and I want to thank everyone involved with the MP. It brought me back from the dead (and I literally mean that.) Forever I felt like a pain in the butt to everyone I met and now thanks to my P.A. and especially my homeopathic I am back among the living, waiting for my first grandchild, and feeling like I LOVE myself just exactly how I am. I also learned that I'm not crazy or a hypocondriac(spelling) and that with a long road to haul I am on a journey of a lifetime. Even with as hard as it gets, I wouldn't change my journey for anything (except to get this FDA approved.) My blessings to all and let the game begin!!!! Shellie



____________________
MP start Mar'12 (no breaks) | Fibromyalgia, Arthritis, CHF, OCD, BPD, trigeminal neuralgia | IBS, visceral hypersensitivity, brain fog, eye inflammation, joint pain, nerve pain. | last 25D=14 ng/ml May 28
keithw
Support Team


Joined: Sun May 24th, 2009
Location: Amphur Sangkha, Surin, Thailand
Posts: 2798
Status:  Offline
 Posted: Tue Jun 5th, 2012 16:18

Quote

Reply
Welcome back Shellie, you are in good company here!:)

:dude:



____________________
WeanPred May09 no breaks SLE, CNS vasculitis, avascular necrosis, arthritis both shoulders Ph1Aug09 Ph2Nov09 Ph3Feb10 25D35(May09)18(Mar10)16.7(Jul10)13.6(Jan11)13.2 (Oct 11)14.8(Aug 12) around 35(Jul14)due to weight loss!
cathys2007
Foundation Staff


Joined: Sun Nov 18th, 2007
Location: Connecticut USA
Posts: 1282
Status:  Offline
 Posted: Thu Jun 21st, 2012 13:00

Quote

Reply
Common Blood Pressure Drug Linked to Severe Gastrointestinal Problems

http://www.sciencedaily.com/releases/2012/06/120621130722.htm

ScienceDaily (June 21, 2012) — Mayo Clinic researchers have discovered an association between a commonly prescribed blood pressure drug, Olmesartan, and severe gastrointestinal issues such as nausea, vomiting, diarrhea, weight loss and electrolyte abnormalities -- symptoms common among those who have celiac disease. The findings are published online June 21 in the medical journal Mayo Clinic Proceedings.



____________________
MP 7/7/08 Dx Sarcoid-determined by lymph node, skin, stomach biopsies/neurosarcoid, FMS, IBS, Chronic Fatigue, brain fog, Primary Parahyperthyroidism, MTHFR, migraines, TMJ, Narcolepsy, Osteopenia, Gerd, Raynauds, Thoracic outlet, poss Lyme/D125=48(Mar07)

 Current time is 13:48
Page:  First Page Previous Page  ...  4  5  6  7  8  9  10  11  12  13  14  Next Page Last Page  



* We can help you understand chronic disease, but only your physician is licensed to give you medical care *

Powered by WowBB 1.7 - Entire site Copyright © 2004-2019 Autoimmunity Research Foundation, All Rights Reserved
Click here to view our PRIVACY POLICY
Page processed in 0.0764 seconds (81% database + 19% PHP). 17 queries executed.